Quick Answer
ABEONA THERAPEUTICS INC. reported Research And Development Expense of $26.81 million for the year ending 2025.
- ABEONA THERAPEUTICS INC. showed a decrease of -22.0% in Research And Development Expense from 2024 to 2025.
- This data is from ABEONA THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $733.0 thousand | Q3 2010: $1.20 million | Q1 2011: $1.12 million | Q2 2011: $903.0 thousand | Q3 2011: $906.0 thousand | Q1 2012: $750.0 thousand | Q2 2012: $654.0 thousand | Q3 2012: $308.0 thousand | Q1 2013: $323.0 thousand | Q2 2013: $197.0 thousand | Q3 2013: $236.0 thousand | Q1 2014: $144.0 thousand | Q2 2014: $81.0 thousand | Q3 2014: $73.0 thousand | Q1 2015: $453.0 thousand | Q2 2015: $610.0 thousand | Q3 2015: $1.58 million | Q1 2016: $1.86 million | Q2 2016: $3.02 million | Q3 2016: $2.75 million | Q1 2017: $2.20 million | Q2 2017: $5.81 million | Q3 2017: $3.28 million | Q4 2017: $5.71 million | Q1 2018: $8.16 million | Q2 2018: $7.92 million | Q3 2018: $13.15 million | Q4 2018: $9.47 million | Q1 2019: $11.74 million | Q2 2019: $16.31 million | Q3 2019: $10.92 million | Q4 2019: $9.61 million | Q1 2020: $6.82 million | Q2 2020: $6.11 million | Q3 2020: $7.97 million | Q1 2021: $8.32 million | Q2 2021: $8.53 million | Q3 2021: $9.06 million | Q1 2022: $10.55 million | Q2 2022: $6.66 million | Q3 2022: $5.49 million | Q1 2023: $8.04 million | Q2 2023: $8.52 million | Q3 2023: $7.15 million | Q1 2024: $7.21 million | Q2 2024: $9.22 million | Q3 2024: $8.94 million | Q1 2025: $9.94 million | Q2 2025: $5.94 million | Q3 2025: $4.22 million.
- Over the full 16 years of available data (2010 to 2025), ABEONA THERAPEUTICS INC.'s Research And Development Expense has grown by 700.6%.
- Historical annual values: Fiscal year 2025: $26.81 million | Fiscal year 2024: $34.36 million | Fiscal year 2023: $31.09 million | Fiscal year 2022: $28.97 million | Fiscal year 2021: $38.73 million | Fiscal year 2020: $30.14 million | Fiscal year 2019: $48.57 million | Fiscal year 2018: $38.70 million | Fiscal year 2017: $16.99 million | Fiscal year 2016: $10.66 million | Fiscal year 2015: $4.72 million | Fiscal year 2014: $333.0 thousand | Fiscal year 2013: $884.0 thousand | Fiscal year 2012: $2.01 million | Fiscal year 2011: $3.58 million | Fiscal year 2010: $3.35 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: